Refine
Has Fulltext
- yes (4)
Is part of the Bibliography
- yes (4)
Document Type
- Journal article (4)
Language
- English (4)
Keywords
- stem-cell transplantation (3)
- therapy (2)
- European experts (1)
- abnormalities (1)
- acute kidney injury (1)
- autologous transplantation (1)
- bone-disease (1)
- bortezomib (1)
- bortezomib plus dxamethasone (1)
- cereblon expression (1)
- consensus statement (1)
- deletion 17P (1)
- disorders (1)
- elderly patients (1)
- enal impairment (1)
- erythropoiesis-stimulating agents (1)
- group consensus statement (1)
- growth-factor receptor 3 (1)
- high-risk cytogenetics (1)
- intergroupe francophone (1)
- monoclonal gammopathy (1)
- multiparameter flow-cytpmetry (1)
- multiparametric flow cytometry (1)
- multiple myeloma (1)
- network (1)
- newly-diagnosed myeloma (1)
- plus dexamethasone (1)
- randomized controlled trial (1)
- randomized phase-3 trial (1)
- recombinant-human-erythropoietin (1)
- thalidomide maintenance (1)
- translocation (1)
- undetermined significance MGUS (1)
- zoledonic acid (1)
Institute
EU-Project number / Contract (GA) number
- 037602 (1)
Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from treatment with pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone among patients in whom bortezomib and lenalidomide treatment had failed. At an updated median follow-up of 15.4 months, the progression-free survival was 4.0 versus 1.9 months (HR, 0.50; P<0.001), and median overall survival was 13.1 versus 8.1 months (HR, 0.72; P=0.009). Pomalidomide plus low-dose dexamethasone, compared with high-dose dexamethasone, improved progression-free survival in patients with del(17p) (4.6 versus 1.1 months; HR, 0.34; P < 0.001), t(4;14) (2.8 versus 1.9 months; HR, 0.49; P=0.028), and in standard-risk patients (4.2 versus 2.3 months; HR, 0.55; P<0.001). Although the majority of patients treated with high-dose dexamethasone took pomalidomide after discontinuation, the overall survival of patients treated with pomalidomide plus low-dose dexamethasone or highdose dexamethasone was 12.6 versus 7.7 months (HR, 0.45; P=0.008) in patients with del(17p), 7.5 versus 4.9 months (HR, 1.12; P=0.761) in those with t(4;14), and 14.0 versus 9.0 months (HR, 0.85; P=0.380) in standard-risk subjects. The overall response rate was higher in patients treated with pomalidomide plus low-dose dexamethasone than in those treated with high-dose dexamethasone both among standard-risk patients (35.2% versus 9.7%) and those with del(17p) (31.8% versus 4.3%), whereas it was similar in patients with t(4; 14) (15.9% versus 13.3%). The safety of pomalidomide plus low-dose dexamethasone was consistent with initial reports. In conclusion, pomalidomide plus low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma and del(17p) and/or t(4;14).